Ibandronate sodium
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 540214

CAS#: 138926-19-9

Description: Ibandronate sodium, also known as Ibandronate sodium monohydrate, is used to treat osteoporosis. It increases bone mineral density, prevents resorption, and decreases osteoclast activity. It may inhibit angiogenesis.


Price and Availability

Size
Price

25mg
USD 180
Size
Price

50mg
USD 310
Size
Price

100mg
USD 565

Ibandronate sodium purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 540214
Name: Ibandronate sodium
CAS#: 138926-19-9
Chemical Formula: C9H24NNaO8P2
Exact Mass: 359.0875
Molecular Weight: 359.22
Elemental Analysis: C, 30.09; H, 6.73; N, 3.90; Na, 6.40; O, 35.63; P, 17.24


Synonym: Boniva; Ibandronate sodium; Ibandronate sodium monohydrate; Sodium trihydrogen (1-hydroxy-3-(methylpentylamino)propylidene)diphosphonate, monohydrate

IUPAC/Chemical Name: sodium hydrogen (1-hydroxy-3-(methyl(pentyl)amino)-1-phosphonopropyl)phosphonate hydrate

InChi Key: VBDRTGFACFYFCT-UHFFFAOYSA-M

InChi Code: InChI=1S/C9H23NO7P2.Na.H2O/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17;;/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17);;1H2/q;+1;/p-1

SMILES Code: CCCCCN(CCC(P([O-])(O)=O)(P(O)(O)=O)O)C.[H]O[H].[Na+]


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Wahl O, Holzgrabe U. Impurity profiling of ibandronate sodium by HPLC-CAD. J Pharm Biomed Anal. 2015 Oct 10;114:254-64. doi: 10.1016/j.jpba.2015.06.002. Epub 2015 Jun 6. PubMed PMID: 26092222.

2: Zhang W, Yang DL, Wang YX, Wang HW, Zhen ZJ, Zhang YZ, Shen Y. In vitro osteoclast-suppressing effect of sodium ibandronate. Chin Med J (Engl). 2013 Feb;126(4):751-5. PubMed PMID: 23422201.

3: Wu SN, Huang YM, Liao YK. Effects of ibandronate sodium, a nitrogen-containing bisphosphonate, on intermediate-conductance calcium-activated potassium channels in osteoclast precursor cells (RAW 264.7). J Membr Biol. 2015 Feb;248(1):103-15. doi: 10.1007/s00232-014-9747-8. Epub 2014 Nov 2. PubMed PMID: 25362532.

4: Tobinai M. [Ibandronate]. Clin Calcium. 2011 Jan;21(1):79-86. doi: CliCa11017986. Review. Japanese. PubMed PMID: 21187598.

5: Recknor C, Czerwinski E, Bone HG, Bonnick SL, Binkley N, Palacios S, Moffett A, Siddhanti S, Ferreira I, Ghelani P, Wagman RB, Hall JW, Bolognese MA, Benhamou CL. Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial. Obstet Gynecol. 2013 Jun;121(6):1291-9. doi: 10.1097/AOG.0b013e318291718c. PubMed PMID: 23812464.

6: Ma Z, Li Y, Zhou M, Huang K, Hu H, Liu X, Xu X. Predictors of Ibandronate Efficacy for the Management of Osteoporosis: A Meta-Regression Analysis. PLoS One. 2016 Mar 1;11(3):e0150203. doi: 10.1371/journal.pone.0150203. eCollection 2016. PubMed PMID: 26930292; PubMed Central PMCID: PMC4773099.

7: Nakamura T, Nakano T, Ito M, Hagino H, Hashimoto J, Tobinai M, Mizunuma H; MOVER Study Group. Clinical efficacy on fracture risk and safety of 0.5 mg or 1 mg/month intravenous ibandronate versus 2.5 mg/day oral risedronate in patients with primary osteoporosis. Calcif Tissue Int. 2013 Aug;93(2):137-46. doi: 10.1007/s00223-013-9734-6. Epub 2013 May 5. PubMed PMID: 23644930; PubMed Central PMCID: PMC3717162.

8: Rossini M, Orsolini G, Adami S, Kunnathully V, Gatti D. Osteoporosis treatment: why ibandronic acid? Expert Opin Pharmacother. 2013 Jul;14(10):1371-81. doi: 10.1517/14656566.2013.795949. Epub 2013 May 7. Review. PubMed PMID: 23650954.

9: Alvarez GS, Echazu MI, Olivetti CE, Desimone MF. Synthesis and characterization of ibandronate-loaded silica nanoparticles and collagen nanocomposites. Curr Pharm Biotechnol. 2015;16(7):661-7. PubMed PMID: 25934976.

10: Hou Y, Gu K, Xu C, Ding H, Liu C, Tuoheti Y. Dose-Effectiveness Relationships Determining the Efficacy of Ibandronate for Management of Osteoporosis: A Meta-Analysis. Medicine (Baltimore). 2015 Jul;94(26):e1007. doi: 10.1097/MD.0000000000001007. Review. PubMed PMID: 26131800; PubMed Central PMCID: PMC4504649.

11: Keating GM. Ibandronate: A Review in Japanese Patients with Osteoporosis. Drugs Aging. 2016 Apr;33(4):295-303. doi: 10.1007/s40266-016-0360-7. Review. PubMed PMID: 26915075.

12: Bergner R, Siegrist B, Gretz N, Pohlmeyer-Esch G, Kränzlin B. Nephrotoxicity of ibandronate and zoledronate in Wistar rats with normal renal function and after unilateral nephrectomy. Pharmacol Res. 2015 Sep;99:16-22. doi: 10.1016/j.phrs.2015.04.016. Epub 2015 May 11. PubMed PMID: 25976681.

13: Park JW, Hwang SR, Jeon OC, Moon HT, Byun Y. Enhanced oral absorption of ibandronate via complex formation with bile acid derivative. J Pharm Sci. 2013 Feb;102(2):341-6. doi: 10.1002/jps.23413. Epub 2012 Dec 11. PubMed PMID: 23233267.

14: Chung YS, Kang HC, Lee T. Comparative Effects of Ibandronate and Paclitaxel on Immunocompetent Bone Metastasis Model. Yonsei Med J. 2015 Nov;56(6):1643-50. doi: 10.3349/ymj.2015.56.6.1643. PubMed PMID: 26446649; PubMed Central PMCID: PMC4630055.

15: Tariq S, Tariq S, Alam SS, Baig M. Effect of ibandronate therapy on serum homocysteine and leptin in postmenopausal osteoporotic females. Osteoporos Int. 2015 Mar;26(3):1187-92. doi: 10.1007/s00198-014-2909-9. Epub 2014 Oct 2. PubMed PMID: 25274281.

16: Chapurlat RD, Laroche M, Thomas T, Rouanet S, Delmas PD, de Vernejoul MC. Effect of oral monthly ibandronate on bone microarchitecture in women with osteopenia-a randomized placebo-controlled trial. Osteoporos Int. 2013 Jan;24(1):311-20. doi: 10.1007/s00198-012-1947-4. Epub 2012 Mar 9. PubMed PMID: 22402673.

17: Kumar MN, Kumar KS, Kumar VJ, Prasanna SJ, Sharma HK, Reddy VK. Stability indicating ion chromatography method for the simultaneous determination of ibandronate sodium drug substance and its impurities. J Pharm Biomed Anal. 2011 Feb 20;54(3):596-601. doi: 10.1016/j.jpba.2010.09.026. Epub 2010 Sep 29. PubMed PMID: 20952141.

18: Miller PD, Recker RR, Reginster JY, Riis BJ, Czerwinski E, Masanauskaite D, Kenwright A, Lorenc R, Stakkestad JA, Lakatos P. Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long-term extension study. Osteoporos Int. 2012 Jun;23(6):1747-56. doi: 10.1007/s00198-011-1773-0. Epub 2011 Sep 28. PubMed PMID: 21953471.

19: Bala Y, Kohles J, Recker RR, Boivin G. Oral ibandronate in postmenopausal osteoporotic women alters micromechanical properties independently of changes in mineralization. Calcif Tissue Int. 2013 Jan;92(1):6-14. doi: 10.1007/s00223-012-9658-6. Epub 2012 Oct 23. PubMed PMID: 23090678.

20: Vitor S, Nunes A, Fonseca C, Freitas J. Ibandronate-associated ischemic colitis: case report. Acta Reumatol Port. 2012 Oct-Dec;37(4):342-4. PubMed PMID: 24126426.